Peripheral artery disease (PAD), the narrowing of arteries that reduces blood flow to the legs and feet, understandably draws interest in any supplement associated with circulation and clot-dissolving activity. Nattokinase has a real body of cardiovascular research behind it, which makes it easy to assume that research extends to PAD specifically. It mostly doesn’t, and it’s worth being precise about what has and hasn’t been studied before anyone with PAD adjusts their regimen based on nattokinase’s broader cardiovascular reputation.
Key Takeaways
- PAD is arterial narrowing, mechanistically distinct from the venous conditions (deep vein thrombosis, superficial vein thrombosis, venous insufficiency) that make up nattokinase’s closest existing vascular-disease research.
- An open-label study of 153 vascular surgery patients with venous conditions, with no placebo group, reported improved symptoms and no adverse drug reactions on nattokinase 100 mg/day, so it cannot show the supplement caused the improvement [3].
- No dedicated, large-scale randomized controlled trial of nattokinase specifically for PAD currently exists.
- PAD management already has established medical treatments (antiplatelet therapy, supervised exercise, statins); nattokinase is not a substitute for any of these.
PAD Is an Arterial Condition, Not a Venous One
Peripheral artery disease results from atherosclerotic narrowing of the arteries supplying the legs, most often caused by plaque buildup rather than a blood clot in the venous system. This distinction matters because most of nattokinase’s more direct vascular-disease evidence comes from studies of venous conditions, deep vein thrombosis, superficial vein thrombosis, and chronic venous insufficiency, which involve blood pooling and clotting in veins, a different physiological process than arterial plaque narrowing.
The Closest Existing Evidence
A study following 153 patients admitted to a vascular surgery department evaluated nattokinase at 100 mg/day for safety and efficacy. The patient population included deep vein thrombosis, superficial vein thrombosis, and venous insufficiency cases, and the study reported improvement in clinical symptoms (p < 0.01) with no adverse drug reactions or drug interactions recorded, but it had no placebo group, so the change cannot be credited to nattokinase [3][1]. This is meaningful safety and symptom data, but it is a venous-disease population, not a PAD-specific arterial-disease trial, and the results shouldn’t be extrapolated to PAD outcomes without that caveat.
Research note: The authors of a 2021 real-world nattokinase study warn that patients on nattokinase alone or with other drugs are at risk of clotting or bleeding, and should have their coagulation monitored [3].
Separately, nattokinase’s broader atherosclerosis research, including the 1,062-participant retrospective, uncontrolled analysis by authors who work for the tablet maker, which reported carotid plaque size down by up to 36% over 12 months at 10,800 FU a day, while a 3,600 FU group saw no lipid or atherosclerosis benefit [2], is relevant to atherosclerotic disease generally and PAD is, mechanistically, an atherosclerotic disease of the leg arteries[2]. But that study measured carotid (neck) artery outcomes, not leg artery blood flow or PAD-specific measures like ankle-brachial index, walking distance, or claudication symptoms, so it’s evidence about the same underlying disease process, not evidence about PAD itself.
The best-controlled test in atherosclerosis was a null result. In a double-blind trial in 265 healthy adults at low cardiovascular risk, 2,000 FU of nattokinase for a median of about three years did not slow carotid artery thickening compared with placebo. Those adults did not have PAD [4].
What Hasn’t Been Studied
No dedicated, adequately powered randomized controlled trial has tested nattokinase specifically against PAD outcomes, ankle-brachial index changes, pain-free walking distance, claudication severity, or need for revascularization. No verified human study of nattokinase on leg or finger blood flow in people with PAD is cited here. This is a genuine evidence gap, not a case where the research exists and simply hasn’t been popularized.
What This Means Practically
PAD already has established, evidence-based medical management: antiplatelet therapy, statins, blood pressure control, smoking cessation, and supervised exercise programs, all of which have dedicated PAD-outcome trials behind them. Nattokinase’s plausible mechanistic overlap with atherosclerotic disease doesn’t substitute for that established care, and anyone with diagnosed PAD considering nattokinase should discuss it with their vascular specialist first, particularly given nattokinase’s bleeding-risk profile and interactions with anticoagulants and antiplatelet medications that PAD patients are often already prescribed.
Frequently Asked Questions
Is there a clinical trial of nattokinase specifically for PAD?
No. No dedicated, large-scale randomized controlled trial has tested nattokinase against PAD-specific outcomes like ankle-brachial index, walking distance, or claudication severity. The closest available evidence comes from venous-disease and general atherosclerosis studies.
Can nattokinase replace PAD medication?
No. PAD has established, evidence-based treatments including antiplatelet therapy, statins, and supervised exercise, all with dedicated PAD-outcome trials behind them. Nattokinase is not a substitute for these and should only be considered alongside a vascular specialist’s guidance.
Is nattokinase risky for someone with PAD?
PAD patients are often already prescribed antiplatelet or anticoagulant medications, and nattokinase’s own bleeding-risk and drug-interaction profile means it should only be added with a physician’s knowledge and oversight.
References
- Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. PMC (2021). PMC8231931
- Chen H et al. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine (2022). PMID 36072877
- Gallelli G et al. Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. Nutrients (2021). PMID 34199189
- Hodis HN et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical hemorheology and microcirculation (2021). PMID 33843667
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
